← All organizations
Highest phase reached
Phase 3
First clinical trial
Jun 1, 2006Last known activity
Mar 29, 2023
Timeline
1990s
- Jun 1, 1998
Onconova Therapeutics, Inc.— Founded
Drugs by trial phase (11 distinct, 32 trials)
Phase 3 (4 own, 0 via acquisition)
Phase 1 (4 own, 0 via acquisition)
Indications
Studied for
- Adenocarcinoma
- Anemia
- Anemia, Refractory
- Anemia, Refractory, with Excess of Blasts
- Carcinoma
- Carcinoma, Hepatocellular
- Carcinoma, Ovarian Epithelial
- Carcinoma, Squamous Cell
- Epidermolysis Bullosa
- Epidermolysis Bullosa Dystrophica
- Esophageal Squamous Cell Carcinoma
- Head and Neck Neoplasms
- Leukemia
- Leukemia, Lymphocytic, Chronic, B-Cell
- Leukemia, Lymphoid
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Leukemia, Myeloid
- Leukemia, Myeloid, Acute
- Leukemia, Myelomonocytic, Chronic
- Leukemia, Myelomonocytic, Juvenile
- Liver Neoplasms
- Lymphoma
- Myelodysplastic Syndromes
- Myeloproliferative Disorders
- Neoplasms
- Ovarian Neoplasms
- Pancreatic Neoplasms
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Preleukemia
- Primary Myelofibrosis
- Splenomegaly
- Squamous Cell Carcinoma of Head and Neck
- Syndrome
- Trisomy
Recent trials (42)
- NCT05705505Study chairPhase 1/Phase 2Mar 29, 2023
- NCT05705505Lead sponsorPhase 1/Phase 2Mar 29, 2023
- NCT04739293Study directorPhase 1May 13, 2021
- NCT04739293Lead sponsorPhase 1May 13, 2021
- NCT04263090CollaboratorPhase 1/Phase 2Feb 29, 2020
- NCT04177498CollaboratorEarly Phase 1Dec 31, 2019
- NCT02730884CollaboratorPhase 2Dec 1, 2016
- NCT02562443Study chairPhase 3Oct 1, 2015
- NCT02562443Lead sponsorPhase 3Oct 1, 2015
- NCT02168725Lead sponsorPhase 1Jun 1, 2014
- NCT02075034Lead sponsorPhase 1May 1, 2014
- NCT02030639Study chairPhase 1Jan 1, 2014
- NCT02107235Lead sponsorPhase 1Jan 1, 2014
- NCT02030639Lead sponsorPhase 1Jan 1, 2014
- NCT01928537Study chairPhase 3Aug 1, 2013
Details
- Founded
- Newtown, PA, US Jun 1, 1998
- Last known activity
- Mar 29, 2023